首页> Cancers> Small-Molecule Inhibitors (SMIs) as an Effective Therapeutic Strategy for Endometrial Cancer.

Small-Molecule Inhibitors (SMIs) as an Effective Therapeutic Strategy for Endometrial Cancer.

导出 OA

翻译打印收藏纠错

第一作者： Cristina,Megino-Luque

第一单位： Oncologic Pathology Group, Department of Basic Medical Sciences, Biomedical Research Institute of Lleida (IRBLleida), University of Lleida, Av. Rovira Roure 80, 25198 Lleida, Spain.;Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Monforte de Lemos 3-5, 28029 Madrid, Spain.

作者： Cristina,Megino-Luque ^[1] ; Cristian Pablo,Moiola ^[2] ; Clara,Molins-Escuder ^[3] ; Carlos,López-Gil ^[2] ; Antonio,Gil-Moreno ^[4] ; Xavier,Matias-Guiu ^[5] ; Eva,Colas ^[4] ; Núria,Eritja ^[6]

作者单位： Oncologic Pathology Group, Department of Basic Medical Sciences, Biomedical Research Institute of Lleida (IRBLleida), University of Lleida, Av. Rovira Roure 80, 25198 Lleida, Spain.;Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Monforte de Lemos 3-5, 28029 Madrid, Spain. ^[1] Gynecology Department-Biomedical Research Group in Gynecology, Vall d'Hebron Research Institute (VHIR), Universitat Autonoma de Barcelona, Pg. Vall d'Hebron119-129, 08035 Barcelona, Spain. ^[2] Oncologic Pathology Group, Department of Basic Medical Sciences, Biomedical Research Institute of Lleida (IRBLleida), University of Lleida, Av. Rovira Roure 80, 25198 Lleida, Spain. ^[3] Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Monforte de Lemos 3-5, 28029 Madrid, Spain.;Gynecology Department-Biomedical Research Group in Gynecology, Vall d'Hebron Research Institute (VHIR), Universitat Autonoma de Barcelona, Pg. Vall d'Hebron119-129, 08035 Barcelona, Spain. ^[4] Oncologic Pathology Group, Department of Basic Medical Sciences, Biomedical Research Institute of Lleida (IRBLleida), University of Lleida, Av. Rovira Roure 80, 25198 Lleida, Spain.;Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Monforte de Lemos 3-5, 28029 Madrid, Spain.;Laboratory of Precision Medicine, Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), Department of Pathology-Hospital, Universitari de Bellvitge, Gran via de l'Hospitalet 199, 08908 Barcelona, Spain. ^[5] Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Monforte de Lemos 3-5, 28029 Madrid, Spain.;Oncologic Pathology Group, Department of Medicine, Biomedical Research Institute of Lleida (IRBLleida), University of Lleida, Av. Rovira Roure 80, 25198 Lleida, Spain. ^[6]

关键词 PI3K/AKT/mTOR clinical trials endometrial cancer receptor tyrosine kinase small-molecule inhibitor

DOI 10.3390/cancers12102751

PMID 32987790

发布时间 2023-11-04

基金项目

CB16/12/00328, CB16/12/00231, PI17/02071 PI17/02155 and CP19/00025/Instituto de Salud Carlos III GCTRA1804MATI/Grupos Estables 2018/Fundación Científica Asociación Española Contra el Cáncer RTC-2017-6261-1/Ministerio de Economía, Industria y Competitividad, Gobierno de España

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交